SOX9 and SOX10 but not BRN2 are required for nestin expression in human melanoma cells

Journal of Investigative Dermatology

Volumn 129, Issue 4, 2009, Pages 945-953

  Flammiger, Anna ^a   Besch, Robert ^a   Cook, Anthony L ^b   Maier, Tanja ^a   Sturm, Richard A ^b   Berking, Carola ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

NESTIN; PROTEIN BRAIN 2; TRANSCRIPTION FACTOR POU; TRANSCRIPTION FACTOR SOX10; TRANSCRIPTION FACTOR SOX9; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MELANOCYTE; MELANOMA; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 63149123596     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2008.316     Document Type: Article

References (35)

1. Andersen B, Rosenfeld G (2001) POU domain factors in the neuroendocrine system: lessons from developmental biology provide insights into human disease. Endocr Rev 22:2-35
2. Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M (2001) Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin. Am J Pathol 158:943-53
3. Besch R, Berking C, Kammerbauer C, Degitz K (2007) Inhibition of urokinase-type plasminogen activator receptor induces apoptosis in melanoma cells by activation of p53. Cell Death Differ 14:818-29
4. Brychtova S, Fiuraskova M, Hlobilkova A, Brychta T, Hirnak J (2007) Nestin expression in cutaneous melanomas and melanocytic nevi. J Cutan Pathol 34:370-5
5. Cook AL, Boyle GM, Leonard JH, Parsons PG, Sturm RA (2006) BRN2 in melanocytic cell development, differentiation, and transformation. In: Hearing VJ, Leong SPL (eds). From Melanocytes to Melanoma: the Progression to Malignancy. Humana Press Inc: Totowa, NY. pp 149-67
6. Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, Herlyn M et al. (2003) Human melanoblasts in culture: expression of BRN2 and synergistic regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest Dermatol 121:1150-9
7. Cook AL, Smith AG, Smit DJ, Leonard H, Sturm RA (2005) Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. Exp Cell Res 308:222-35
8. Dahlstrand J, Collins VP, Lendahl U (1992a) Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 52:5334-41
9. Dahlstrand J, Zimmerman LB, McKay RDG, Lehndahl U (1992b) Characterization of the human nestin gene reveals a close evolutionary relationship to neurofilaments. J Cell Sci 103:589-97
10. Dailey L, Basilico C (2001) Coevolution of HMG domains and homeodomains and the generation of transcriptional regulation by Sox/POU complexes. J Cell Physiol 186:315-28
11. Ehrmann J, Kolar Z, Mokry J (2005) Nestin as a diagnostic and prognostic marker: immunohistochemical analysis of its expression in different tumours. J Clin Pathol 58:222-3
12. Eisen T, Easty DJ, Bennett DC, Goding CR (1995) The pou domain transcription factor Brn-2: elevated expression in malignant melanoma and regulation of melanocyte-specific gene expression. Oncogene 11:2157-64
13. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S et al. (2005) A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res 65:9328-37
14. Finzsch M, Stolt CC, Lommes P, Wegner M (2008) Sox9 and Sox10 influence survival and migration of oligodendrocyte precursors in the spinal cord by regulating PDGF receptor alpha expression. Development 135:637-46
15. Florenes VA, Holm R, Myklebost O, Lendahl U, Fodstad O (1994) Expression of the neuroectodermal intermediate filament nestin in human melanomas. Cancer Res 54:354-6
16. Goodall J, Martinozzi S, Dexter TJ, Champeval D, Carreira S, Larue L et al. (2004a) Brn-2 expression controls melanoma proliferation and is directly regulated by b-catenin. Mol Cell Biol 24:2915-22
17. Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR (2004b) The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24:2923-31
18. Grichnik JM, Burch JA, Schulteis RD, Shan S, Liu J, Darrow TL et al. (2006) Melanoma, a tumor based on a mutant stem cell? J Invest Dermatol 126:142-53
19. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE et al. (1985) Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 45:5670-6
20. Huang EH, Heidt DG, Li CW, Simeone DM (2007) Cancer stem cells: a new paradigm for understanding tumor progression and therapeutic resistance. Surgery 141:415-9
21. Josephson R, Müller T, Pickel J, Okabe S, Reynolds K, Turner PA et al. (1998) POU transcription factors control expression of CNS stem cell-specific genes. Development 125:3087-100
22. Kamstrup MR, Gniadecki R, Skovgaard GL (2007) Putative cancer stem cells in cutaneous malignancies. Exp Dermatol 16:297-301
23. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJP, Tahan SR (2007) Increased expression of stem cell markers in malignant melanoma. Mod Pathol 20:102-7
24. Michalczyk K, Ziman M (2005) Nestin structure and predicted function in cellular cytoskeletal organisation. Histol Histopathol 20:665-71
25. Moon C, Ahn M, Kim S, Jin JK, Sim KB, Kim HM et al. (2004) Temporal patterns of the embryonic intermediate filaments nestin and vimentin expression in the cerebral cortex of adult rats after cryoinjury. Brain Res 1028:238-42
26. Passeron T, Valencia JC, Bertolotto C, Hoashi T, Le Pape E, Takahashi K et al. (2007) SOX9 is a key player in ultraviolet B-induced melanocyte differentiation and pigmentation. Proc Natl Acad Sci USA 104:13984-9
27. Smalley KSM, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M (2006) Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5:1136-44
28. Smit DJ, Smith AG, Parsons PG, Muscat GE, Sturm RA (2000) Domains of Brn-2 that mediate homodimerization and interaction with general and melanocytic transcription factors. Eur J Biochem 267:6413-22
29. Smith AG, Brightwell G, Smit SE, Parsons PG, Sturm RA (1998) Redox regulation of Brn-2/N-Oct-3 POU domain DNA binding activity and proteolytic formation of N-Oct-5 during melanoma cell nuclear extraction. Melanoma Res 8:2-10
30. Steinert PM, Chou YH, Prahlad V, Parry DAD, Marekov LN, Wu KC et al. (1999) A high molecular weight intermediate filament-associated protein in BHK-21 cells is nestin, a type VI intermediate filament protein. J Biol Chem 274:9881-90
31. Sturm RA, O'Sullivan BJ, Thomson JA, Jamshidi N, Pedley J, Parsons PG (1994) Expression studies of pigmentation and POU-domain genes in human melanoma cells. Pigment Cell Res 7:235-40
32. Sunabori T, Tokunaga A, Nagai T, Sawamoto K, Okabe M, Miyawaki A et al. (2008) Cell-cycle-specific nestin expression coordinates with morphological changes in embryonic cortical neural progenitors. J Cell Sci 121:1204-12
33. Tanaka S, Kamachi Y, Tanouchi A, Hamada H, Jing N, Kondoh H (2004) Interplay of SOX and POU factors in regulation of the nestin gene in neural primordial cells. Mol Cell Biol 24:8834-46
34. Thomson JAF, Murphy K, Baker E, Sutherland GR, Parsons PG, Sturm RA (1995) The brn-2 gene regulates the melanocytic phenotype and tumorigenic potential of human melanoma cells. Oncogene 11:691-700
35. Wegner M (2005) Secrets to a healthy Sox life: lessons for melanocytes. Pigment Cell Res 18:74-85